Satellos Bioscience Inc.
NASDAQ: MSLE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Frank Gleeson
- Employees
- 18
- Headquarters
- Toronto, Canada
- IPO year
- 2012
- Market cap
- $9.8M
- Website
- https://satellos.com
Loading MSLE…
Loading profile data…Frequently asked questions about MSLE
What does Satellos Bioscience Inc. (MSLE) do?
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate...
Where does MSLE trade?
Satellos Bioscience Inc. (MSLE) trades on the NASDAQ.
What sector is MSLE in?
Satellos Bioscience Inc. (MSLE) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Satellos Bioscience Inc.?
Frank Gleeson is the chief executive officer of Satellos Bioscience Inc. (MSLE).
Where is Satellos Bioscience Inc. headquartered?
Satellos Bioscience Inc. is headquartered in Canada.
Does MSLE pay a dividend?
Satellos Bioscience Inc. (MSLE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MSLE go public?
Satellos Bioscience Inc. (MSLE) completed its initial public offering in 2012.